Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | PHASE1 | COMPLETED | 132 | — | — | Jun 27, 2018 | Dec 30, 2024 | Jan 15, 2025 | 59 | United States, Greece +4 |
Assess dose limiting toxicity as defined in the protocol
Frequency and severity of AEs and/or SAEs
Proportion of patients who achieve a confirmed CR or PR
| Arm | Type | Description |
|---|---|---|
| Monotherapy - CAB-ROR2-ADC (BA3021) alone | EXPERIMENTAL | BA3021 alone Q2W dosing regimen |
| Combination Therapy | EXPERIMENTAL | CAB-ROR2-ADC (BA3021) with PD-1 inhibitor |
| Name | Type | Description |
|---|---|---|
| CAB-ROR2-ADC | BIOLOGICAL | Conditionally active biologic anti-ROR2 antibody drug conjugate |
| PD-1 inhibitor | BIOLOGICAL | PD-1 inhibitor |
Inclusion Criteria: * Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse stan...